Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Design and analysis of three-arm trials with negative binomially distributed endpoints.
Decade in review-multiple sclerosis: New drugs and personalized medicine for multiple sclerosis.
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.
Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis.
An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex.
Development of a high-resolution fat and CSFsuppressed optic nerve DTI protocol at 3T: application in multiple sclerosis.
TH17 cell differentiation is regulated by the circadian clock.
Comparison of BLADE and conventional T2-TSE sequences for the sagittal visualization of the cervical spinal cord in multiple sclerosis patients - A case report.
The New Era of Multiple Sclerosis Therapeutics.
The role of mast cells in neuroinflammation.
Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors.
Application of the fuzzy logic concept in the multiple sclerosis functional composite for scoring the progress of multiple sclerosis.
Anorectal dysfunction in multiple sclerosis: a systematic review.
MRI correlates of disability in african-americans with multiple sclerosis.
Microstructural changes in the striatum and their impact on motor and neuropsychological performance in patients with multiple sclerosis.
Immunosuppressive treatments in multiple sclerosis.
The Contributions of Solar Ultraviolet Radiation Exposure and Other Determinants to Serum 25-Hydroxyvitamin D Concentrations in Australian Adults: The AusD Study.
Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.
Myeloid microvesicles are a marker and therapeutic target for neuroinflammation.
Alemtuzumab for multiple sclerosis: who and when to treat?
Associated with intrathecal baclofen treatment and duloxetine in patients with multiple sclerosis.
Mobility and cognitive correlates of dual task cost of walking in persons with multiple sclerosis.
Multiple sclerosis: managing a complex neurological disease.
Multiple sclerosis, blood flow, and CSF circulation.
Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1/M23 isoform content, or supramolecular assembly.
Pages
« first
‹ previous
…
267
268
269
270
271
272
273
274
275
…
next ›
last »